“…Our results are consistent with past studies showing that serum levels of NF-L are higher in people with diverse neurological and neurodegenerative conditions. Researchers have reported that serum levels of NF-L are higher in people with multiple sclerosis (Kuhle et al, 2016;Disanto et al, 2017;Kuhle et al, 2017;Novakova et al, 2017), acute ischemic stroke (De Marchis et al, 2018), active cerebral small vessel disease (Gattringer et al, 2017), familial Alzheimer's disease (Mattsson et al, 2017;Weston et al, 2017), Huntington's disease (Byrne et al, 2017), frontotemporal dementia (Rohrer et al, 2016), Creutzfeldt-Jakob disease (Thompson et al, 2018), Parkinsonian disorders (Hansson et al, 2017), other degenerative ataxias such as multiple system atrophy (Wilke et al, 2018) and amyotrophic lateral sclerosis (Feneberg et al, 2018).…”